BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Van Ginderdeuren E, Bassett J, Hanrahan CF, Mutunga L, Van Rie A. Novel health system strategies for tuberculin skin testing at primary care clinics: Performance assessment and health economic evaluation. PLoS One 2021;16:e0246523. [PMID: 33596215 DOI: 10.1371/journal.pone.0246523] [Reference Citation Analysis]
2 Nabity SA, Gunde LJ, Surie D, Shiraishi RW, Kirking HL, Maida A, Auld AF, Odo M, Jahn A, Nyirenda RK, Oeltmann JE. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). PLoS One 2021;16:e0248115. [PMID: 33793577 DOI: 10.1371/journal.pone.0248115] [Reference Citation Analysis]
3 Haas MK, Belknap RW. Diagnostic Tests for Latent Tuberculosis Infection. Clin Chest Med 2019;40:829-37. [PMID: 31731987 DOI: 10.1016/j.ccm.2019.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
4 Delogu G, Vanini V, Cuzzi G, Chiacchio T, De Maio F, Battah B, Pinnetti C, Sampaolesi A, Antinori A, Goletti D. Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. Scand J Immunol 2016;84:344-52. [PMID: 27636597 DOI: 10.1111/sji.12493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
5 Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 2018;78:54-61. [PMID: 29406428 DOI: 10.1097/QAI.0000000000001641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Alemu A, Yesuf A, Gebrehanna E, Zerihun B, Getu M, Worku T, Bitew ZW. Incidence and predictors of extrapulmonary tuberculosis among people living with Human Immunodeficiency Virus in Addis Ababa, Ethiopia: A retrospective cohort study. PLoS One 2020;15:e0232426. [PMID: 32374773 DOI: 10.1371/journal.pone.0232426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Katale BZ, Mbelele PM, Lema NA, Campino S, Mshana SE, Rweyemamu MM, Phelan JE, Keyyu JD, Majigo M, Mbugi EV, Dockrell HM, Clark TG, Matee MI, Mpagama S. Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. BMC Genomics 2020;21:174. [PMID: 32085703 DOI: 10.1186/s12864-020-6577-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Escudero JN, Hawn TR, John-Stewart GC. Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children. BMJ Open 2020;10:e034308. [PMID: 31969368 DOI: 10.1136/bmjopen-2019-034308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Sci Rep 2020;10:21823. [PMID: 33311520 DOI: 10.1038/s41598-020-78737-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis 2020;20:294. [PMID: 32664847 DOI: 10.1186/s12879-020-05011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lee CY, Wu PH, Lu PL, Liang FW. Different Trends of Distinct Time Points of AIDS Events Following HIV Diagnosis in Various At-risk Populations: A Retrospective Nationwide Cohort Study in Taiwan. Infect Dis Ther 2021;10:1715-32. [PMID: 34245451 DOI: 10.1007/s40121-021-00494-8] [Reference Citation Analysis]
12 Santos DTD, Garcia MC, Costa AANFD, Pieri FM, Meier DAP, Albanese SPR, Arcêncio RA, Dessunti EM. [Latent tuberculosis infection in persons with HIV/AIDS, associated factors, and progression to active disease in a city in southern Brazil]. Cad Saude Publica 2017;33:e00050916. [PMID: 28832776 DOI: 10.1590/0102-311X00050916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med 2020;201:598-605. [PMID: 31711306 DOI: 10.1164/rccm.201908-1606OC] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Turetz ML, Ma KC. Diagnosis and management of latent tuberculosis. Curr Opin Infect Dis 2016;29:205-11. [PMID: 26836374 DOI: 10.1097/QCO.0000000000000253] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
15 Marks SM, Katz DJ, Davidow AL, Pagaoa MA, Teeter LD, Graviss EA. The Impact of HIV Infection on TB Disparities Among US-Born Black and White Tuberculosis Patients in the United States. J Public Health Manag Pract 2020;26:E5-E12. [PMID: 32732731 DOI: 10.1097/PHH.0000000000000949] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ferguson O, Jo Y, Pennington J, Johnson K, Chaisson RE, Churchyard G, Dowdy D. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2020;23:e25623. [PMID: 33073520 DOI: 10.1002/jia2.25623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Goscé L, Abou Jaoude GJ, Kedziora DJ, Benedikt C, Hussain A, Jarvis S, Skrahina A, Klimuk D, Hurevich H, Zhao F, Fraser-Hurt N, Cheikh N, Gorgens M, Wilson DJ, Abeysuriya R, Martin-Hughes R, Kelly SL, Roberts A, Stuart RM, Palmer T, Panovska-Griffiths J, Kerr CC, Wilson DP, Haghparast-Bidgoli H, Skordis J, Abubakar I. Optima TB: A tool to help optimally allocate tuberculosis spending. PLoS Comput Biol 2021;17:e1009255. [PMID: 34570767 DOI: 10.1371/journal.pcbi.1009255] [Reference Citation Analysis]
18 Wu X, Pang Y, Song Y, Dong W, Zhang T, Wen S, Huang H, Gao M. Implications of a school outbreak of multidrug-resistant tuberculosis in Northern China. Epidemiol Infect 2018;146:584-8. [DOI: 10.1017/s0950268817003120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
19 Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Ngabirano C, Adong J, Linas BP, Jacobson KR, Hahn JA. Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. PLoS One 2020;15:e0235261. [PMID: 32614873 DOI: 10.1371/journal.pone.0235261] [Reference Citation Analysis]
20 Moreira DS, Xavier MV, Murta SMF. Ascorbate peroxidase overexpression protects Leishmania braziliensis against trivalent antimony effects. Mem Inst Oswaldo Cruz 2018;113:e180377. [PMID: 30507997 DOI: 10.1590/0074-02760180377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
21 Behrens RH. Isoniazid prophylaxis for the prevention of travel associated tuberculosis. J Travel Med 2016;23:taw030. [DOI: 10.1093/jtm/taw030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Chimbetete C, Shamu T, Roelens M, Bote S, Mudzviti T, Keiser O. Mortality trends and causes of death among HIV positive patients at Newlands Clinic in Harare, Zimbabwe. PLoS One 2020;15:e0237904. [PMID: 32853215 DOI: 10.1371/journal.pone.0237904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
24 Picone CM, Freitas AC, Gutierrez EB, Avelino-Silva VI. Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 2020;62:e8. [PMID: 32049259 DOI: 10.1590/S1678-9946202062008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Majigo M, Somi G, Joachim A, Manyahi J, Nondi J, Sambu V, Rwebembera A, Makyao N, Ramadhani A, Maokola W, Todd J, Matee MI. Prevalence and incidence rate of tuberculosis among HIV-infected patients enrolled in HIV care, treatment, and support program in mainland Tanzania. Trop Med Health 2020;48:76. [PMID: 33579394 DOI: 10.1186/s41182-020-00264-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr 2017;5. [PMID: 28233512 DOI: 10.1128/microbiolspec.TNMI7-0028-2016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
27 Nabity SA, Mponda K, Gutreuter S, Surie D, Williams A, Sharma AJ, Schnaubelt ER, Marshall RE, Kirking HL, Zimba SB, Sunguti JL, Chisuwo L, Chiwaula MJ, Gregory JF, da Silva R, Odo M, Jahn A, Kalua T, Nyirenda R, Girma B, Mpunga J, Buono N, Maida A, Kim EJ, Gunde LJ, Mekonnen TF, Auld AF, Muula AS, Oeltmann JE. Protocol for a Case-Control Study to Investigate the Association of Pellagra With Isoniazid Exposure During Tuberculosis Preventive Treatment Scale-Up in Malawi. Front Public Health 2020;8:551308. [PMID: 33324593 DOI: 10.3389/fpubh.2020.551308] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab319. [PMID: 34395707 DOI: 10.1093/ofid/ofab319] [Reference Citation Analysis]
29 Wyndham-Thomas C, Dirix V, Goffard JC, Henrard S, Wanlin M, Callens S, Mascart F, Van Vooren JP. 2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. Acta Clin Belg 2019;74:242-51. [PMID: 30036162 DOI: 10.1080/17843286.2018.1494669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Naidoo K, Gengiah S, Singh S, Stillo J, Padayatchi N. Quality of TB care among people living with HIV: Gaps and solutions. J Clin Tuberc Other Mycobact Dis 2019;17:100122. [PMID: 31788564 DOI: 10.1016/j.jctube.2019.100122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Takarinda KC, Choto R, Sandy C, Apollo T, Duri C, Dube F, Mpofu A, Timire C, Mugurungi O, Makaza V, Tapera R, Harries AD. How well does the process of screening and diagnosis work for HIV-infected persons identified with presumptive tuberculosis who are attending HIV care and treatment clinics in Harare city, Zimbabwe? Trans R Soc Trop Med Hyg 2018;112:450-7. [PMID: 30032237 DOI: 10.1093/trstmh/try073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Collin SM, Wurie F, Muzyamba MC, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D. Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews. Eur Respir Rev 2019;28:180107. [PMID: 31142548 DOI: 10.1183/16000617.0107-2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Alemu A, Yesuf A, Zerihun B, Getu M, Worku T, Bitew ZW. Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study. Int J Infect Dis 2020;95:59-66. [PMID: 32126324 DOI: 10.1016/j.ijid.2020.02.053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Thindwa D, MacPherson P, Choko AT, Khundi M, Sambakunsi R, Ngwira LG, Kalua T, Webb EL, Corbett EL. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. Int J Tuberc Lung Dis 2018;22:273-9. [PMID: 29471904 DOI: 10.5588/ijtld.17.0370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
36 Boyd AT, Odume B, Sidibe K, Onotu D, Ogbanufe O, Mgbakor I, Swaminathan M. Brief Report: Programmatic Scale-up of Tuberculosis Preventive Treatment Among People Living With HIV Through Targeted Technical Assistance to High-Volume Antiretroviral Treatment Sites-Nigeria, 2018-2019. J Acquir Immune Defic Syndr 2020;85:450-3. [PMID: 33136743 DOI: 10.1097/QAI.0000000000002483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Freiman JM, Jacobson KR, Muyindike WR, Horsburgh CR, Ellner JJ, Hahn JA, Linas BP. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. J Acquir Immune Defic Syndr 2018;77:405-12. [PMID: 29239900 DOI: 10.1097/QAI.0000000000001610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
38 Singh A, Prasad R, Balasubramanian V, Gupta N. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl) 2020;12:9-31. [PMID: 32021483 DOI: 10.2147/HIV.S193059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Van Ginderdeuren E, Bassett J, Hanrahan CF, Mutunga L, Van Rie A. High conversion of tuberculin skin tests during the first year of antiretroviral treatment among South African adults in primary care. AIDS 2021;35:1775-84. [PMID: 34014852 DOI: 10.1097/QAD.0000000000002952] [Reference Citation Analysis]
40 Norrby M, Wannheden C, Ekström AM, Berggren I, Lindquist L. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013. Infect Dis (Lond) 2018;50:807-16. [PMID: 30362392 DOI: 10.1080/23744235.2018.1486511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Howard AA, Hirsch-Moverman Y, Saito S, Gadisa T, Daftary A, Melaku Z. The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods cluster randomized trial. Contemp Clin Trials Commun 2017;6:46-54. [PMID: 28626811 DOI: 10.1016/j.conctc.2017.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Agudelo CA, Álvarez MF, Hidrón A, Villa JP, Echeverri-Toro LM, Ocampo A, Porras GP, Trompa IM, Restrepo L, Eusse A, Restrepo CA. Outcomes and complications of hospitalised patients with HIV-TB co-infection. Trop Med Int Health 2021;26:82-8. [PMID: 33155342 DOI: 10.1111/tmi.13509] [Reference Citation Analysis]
43 Montales MT, Chaudhury A, Beebe A, Patil S, Patil N. HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide. Front Public Health 2015;3:281. [PMID: 26779470 DOI: 10.3389/fpubh.2015.00281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
44 Surie D, Borgdorff MW, Cain KP, Click ES, DeCock KM, Yuen CM. Assessing the impact of antiretroviral therapy on tuberculosis notification rates among people with HIV: a descriptive analysis of 23 countries in sub-Saharan Africa, 2010-2015. BMC Infect Dis 2018;18:481. [PMID: 30257667 DOI: 10.1186/s12879-018-3387-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
45 Seid MA, Ayalew MB, Muche EA, Gebreyohannes EA, Abegaz TM. Drug-susceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis. BMJ Open 2018;8:e022111. [PMID: 30257846 DOI: 10.1136/bmjopen-2018-022111] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]